Compare Victoria's Secret & Co (VSXY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Victoria's Secret & Co vs GeneDx Holdings Corp — how do they compare? Victoria's Secret & Co trades at $82.87 (market cap $6.91B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Victoria's Secret & Co is far larger — about 3.4× GeneDx Holdings Corp's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Victoria's Secret & Co for 34 Days and GeneDx Holdings Corp for 19 Days on average.
| VSXY | WGS | |
|---|---|---|
Market Cap | $6.91B | $2.02B |
Volume | 1,346,928 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $99.97 | $167.51 |
52-Week Low | $28.25 | $34.51 |
Typical Hold Time | 34 Days | 19 Days |
Enterprise Value | $9.29B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Victoria's Secret (VSXY) trades at $82.87, down 3.4% on the day, but maintains strong analyst support with a 60% buy rating and $86.80 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q4 2025 and Q1-Q2 2026, while fundamentals reveal improving profitability with 39.57% gross margins and 45.27% ROE. Recent news highlights brand momentum through fashion show expansions and omnichannel retail growth.
The outlook remains positive with projected 2026 revenue growth to $6.9B and net income of $378M, though risks include elevated valuation metrics (P/E 19.33) and competitive pressures. Institutional interest is strengthening with recent investments from Tidal Investments and California State Teachers Retirement System, supporting the bullish case for long-term investors.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
